Dae Hoon Jeong

Dae Hoon Jeong

Auto-generated profile, based on publicly available information

Dae Hoon Jeong

Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, Busan, Korea

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
DJD.H. Jeong
D.H. Jeong
MYM.Y. Youm
M.Y. Youm
YKY.N. Kim
Y.N. Kim
KLK.B. Lee
K.B. Lee
MSM.S. Sung
M.S. Sung
KKK.T. Kim
K.T. Kim

1 January 2022 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
JPJunsik Park
Junsik Park
MLMyong Cheol Lim
Myong Cheol Lim
JLjae kwan lee
jae kwan lee
DJDae Hoon Jeong
Dae Hoon Jeong
SKSe Ik Kim
Se Ik Kim
JLJung-Yun Lee
Jung-Yun Lee
Park J, et al. J Gynecol Oncol. 2021 Dec;33:e12. https://doi.org/10.3802/jgo.2022.33.e12

1 July 2019 in Acta Oncologica
Verified
Journal Article
Closed access
JBJung Mi Byun
Jung Mi Byun
DLDae Sim Lee
Dae Sim Lee
CLCharles N. Landen
Charles N. Landen
DKDa Hyun Kim
Da Hyun Kim
YKYoung Nam Kim
Young Nam Kim
DJDae Hoon Jeong
Dae Hoon Jeong
Background: Arsenic compounds (As2O3 and As4O6) have demonstrated anticancer effects in various malignancies. In this study, the cytotoxicity of arsenic compounds on ovarian cancer cell lines and the anticancer activity of the combination of arsenic compounds and cisplatin IN chemoresistant ovarian cancer cells were investigated. Methods: We investigated the cytotoxicity of As2O3 and As4O6 and their combinations with cisplatin in the paclitaxel-sensitive ovarian cancer cell lines SKOV3ip1 and HeyA8 and paclitaxel-resistant ovarian cancer cell lines SKOV3TRip2 and HeyA8-MDR. Growth and apoptosis were evaluated by MTT assay and annexin V assay using flow cytometry, respectively. For detection of apoptotic cells, immunofluorescence was performed using a cleaved caspase-3 antibody. Cell-cycle distribution was determined by propidium iodide staining and flow cytometry. Results: Treatment of each cell line with As2O3 or As4O6 led to a marked dose-dependent inhibition of cell growth. As2O3 and As4O6 treatment induced caspase-3-dependent apoptosis in all cell lines compared to the respective control groups (p < .05). As2O3 and As4O6 induced apoptosis of paclitaxel-sensitive and -resistant cancer cell lines following G2/M cell cycle arrest (p < .05). A synergistic effect was achieved by combining cisplatin with As2O3 or As4O6 in the paclitaxel-resistant ovarian cancer cell lines. Conclusions: As2O3 and As4O6 can inhibit cell growth and induce apoptosis in paclitaxel-sensitive and -resistant ovarian cancer cell lines. Their combination with cisplatin resulted in a synergistic effect in paclitaxel-resistant cancer cell lines. These results suggest that arsenic compounds may be given in monotherapy or combination therapy with cisplatin for treating paclitaxel-resistant ovarian cancer.

1 January 2020 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
JSJaehyun Seong
Jaehyun Seong
SRSangmi Ryou
Sangmi Ryou
MYMyeongsu Yoo
Myeongsu Yoo
JLJeongGyu Lee
JeongGyu Lee
KKKisoon Kim
Kisoon Kim
MKMee-Kyung Kee
Mee-Kyung Kee
Since 2007, human papillomavirus (HPV) vaccines have been administered for the prevention of cervical cancer in Korea. We investigated the status of HPV vaccination among HPV-infected adult women with abnormal cervical cytology before the introduction of National Immunization Program. From 2010 to 2016, HPV-positive women (age, 20-60 years) with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion (LSIL) were enrolled from five hospitals across Korea. Their HPV genotype, epidemiologic, and clinical data, including HPV vaccination history, were obtained. We compared the epidemiological characteristics and prevalence of HPV-16/18 genotypes between vaccinated and unvaccinated women. Among the 1,300 women, approximately 26% had a history of vaccination. Vaccinated patients were significantly younger, unmarried, and had a higher education level than unvaccinated women. For HPV-vaccinated individuals by vaccine dose, there was a significant younger age at vaccination initiation (p=0.025), longer duration from HPV vaccination to Pap test date (p=0.001), and lower proportion of HPV-16/18 (p=0.028) in the women with three doses. There was a significantly lower prevalence of HPV-16/18 genotypes in women who were vaccinated at least 12 months prior than in unvaccinated women (adjusted prevalence ratio [aPR]=0.51; 95% confidence interval [CI]=0.29-0.88). For women with LSIL, the prevalence of the HPV-16/18 genotypes was significantly lower in women who were vaccinated more than 12 months prior than in unvaccinated women (aPR=0.35; 95% CI=0.13-0.96). This study highlighted the status of HPV vaccination and the prevalence of HPV-16/18 genotypes among HPV-infected women with abnormal cervical cytology according to HPV vaccination. It provides preliminary information regarding the status of HPV vaccination among Korean adult women.

1 January 2017 in Obstetrics & Gynecology Science
Verified
Journal Article
Open access
PDF file
YPYong Hee Park
Yong Hee Park
EJEun Jung Jung
Eun Jung Jung
JBJung Mi Byun
Jung Mi Byun
MAMin Sung An
Min Sung An
YKYoung Nam Kim
Young Nam Kim
DJDae Hoon Jeong
Dae Hoon Jeong
Park YH, et al. Obstet Gynecol Sci. 2017 Nov;60(6):608-611. https://doi.org/10.5468/ogs.2017.60.6.608

22 October 2012 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
IJI.H. Jo
I.H. Jo
YKYong-Nyun Kim
Yong-Nyun Kim
YSY.J. Seo
Y.J. Seo
JBJ.M. Byun
J.M. Byun
DJD.H. Jeong
D.H. Jeong
KKK.T. Kim
K.T. Kim